Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT by Ahmad Saad, Fathinul Fikri et al.
Localization and prediction of malignant potential in recurrent 
pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT 
 
ABSTRACT 
Background: To our knowledge, data are lacking on the role of 18F-FDG PET/CT in the 
localization and prediction of neuroendocrine tumors, in particular the 
pheochromocytoma/paraganglioma (PCC/PGL) group. Purpose: To evaluate the role of 18F-
FDG PET/CT in localizing and predicting the malignant potential of PCC/PGL. Material and 
Methods: Twenty-three consecutive patients with a history of PCC/PGL, presenting with 
symptoms related to catecholamine excess, underwent 18F-FDG PET/CT. Final confirmation 
of the diagnosis was made using the composite references. PET/CT findings were analyzed 
on a per-lesion basis and a per-patient basis. Tumor SUVmax was analyzed to predict the 
dichotomization of patient endpoints for the local disease and metastatic groups. Results: We 
investigated 23 patients (10 men, 13 women) with a mean age of 46.43±3.70 years. Serum 
catecholamine levels were elevated in 82.60% of these patients. There were 136 sites (mean 
SUVmax: 16.39±3.47) of validated disease recurrence. The overall sensitivities for diagnostic 
CT, FDG PET, and FDG PET/CT were 86.02%, 87.50%, and 98.59%, respectively. Based on 
the composite references, 39.10% of patients had local disease. There were significant 
differences in the SUVmax distribution between the local disease and metastatic groups; a 
significant correlation was noted when a SUVmax cut-off was set at 9.2 (P<0.05). 
Conclusion: In recurrent PCC/PGL, diagnostic 18F-FDG PET/CT is a superior tool in the 
localization of recurrent tumors. Tumor SUVmax is a potentially useful predictor of 
malignant tumor potential. 
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